Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

20.06.2022 | main topic

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis

Immunotherapy with rituximab, ocrelizumab, and ofatumumab

verfasst von: Arkady Ovchinnikov, Dr.med. Oliver Findling

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration of brain tissue. For a long time, research focused on T cells as the primary mechanism of disease. Driven by reports on the clinical results of B cell-depleting therapies, this therapeutic approach has come into focus in the last decade, and new highly effective treatments have been developed and are now complementing the therapeutic landscape. This review provides an overview of the development of B cell-depleting therapies and shows the advantages and disadvantages of current developments. In addition, we discuss basic considerations for CD20-depleted MS patients in the face of the COVID-19 pandemic.
Literatur
1.
Zurück zum Zitat Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. CrossRef Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. CrossRef
3.
Zurück zum Zitat Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8. CrossRef Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8. CrossRef
4.
Zurück zum Zitat Murphy K, Travers P, Walport M. Janeway’s immunobiology. 3rd ed. New York: Garland Science; 2008. Murphy K, Travers P, Walport M. Janeway’s immunobiology. 3rd ed. New York: Garland Science; 2008.
5.
Zurück zum Zitat Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663–4. CrossRef Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663–4. CrossRef
6.
Zurück zum Zitat Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580–6. CrossRef Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580–6. CrossRef
7.
Zurück zum Zitat Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. CrossRef Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. CrossRef
8.
Zurück zum Zitat Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Rheumatol Clin. 2011;7(5):314–22. Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Rheumatol Clin. 2011;7(5):314–22.
9.
Zurück zum Zitat Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400. CrossRef Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400. CrossRef
10.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88. CrossRef Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88. CrossRef
11.
Zurück zum Zitat de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to Rituximab. Neurology. 2016;87(2):141–7. CrossRef de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to Rituximab. Neurology. 2016;87(2):141–7. CrossRef
13.
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34. CrossRef Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34. CrossRef
14.
Zurück zum Zitat Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20. CrossRef Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20. CrossRef
15.
Zurück zum Zitat Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573–81. CrossRef Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573–81. CrossRef
16.
Zurück zum Zitat Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90(20):e1805–e14. CrossRef Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90(20):e1805–e14. CrossRef
17.
Zurück zum Zitat Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–57. CrossRef Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–57. CrossRef
18.
Zurück zum Zitat Berntsson SG, Kristoffersson A, Bostrom I, Feresiadou A, Burman J, Landtblom AM. Rapidly increasing off-label use of Rituximab in multiple sclerosis in Sweden—Outlier or predecessor? Acta Neurol Scand. 2018;138(4):327–31. CrossRef Berntsson SG, Kristoffersson A, Bostrom I, Feresiadou A, Burman J, Landtblom AM. Rapidly increasing off-label use of Rituximab in multiple sclerosis in Sweden—Outlier or predecessor? Acta Neurol Scand. 2018;138(4):327–31. CrossRef
19.
Zurück zum Zitat Salzer J, Svenningsson R, Alpine P, Novakova L, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–81. CrossRef Salzer J, Svenningsson R, Alpine P, Novakova L, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–81. CrossRef
22.
Zurück zum Zitat Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of Rituximab. Rev Med Virol. 2019;29(6):e2077. CrossRef Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of Rituximab. Rev Med Virol. 2019;29(6):e2077. CrossRef
23.
Zurück zum Zitat Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738–44. CrossRef Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738–44. CrossRef
26.
Zurück zum Zitat Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Baroni A, Lapucci C, et al. Effect of SARS-CoV‑2 mRNA vaccination in MS patients treated with disease-modifying therapies. eBioMedicine. 2021;72:103581. CrossRef Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Baroni A, Lapucci C, et al. Effect of SARS-CoV‑2 mRNA vaccination in MS patients treated with disease-modifying therapies. eBioMedicine. 2021;72:103581. CrossRef
27.
Zurück zum Zitat Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-coV‑2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021;78(12):1529–31. CrossRef Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-coV‑2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021;78(12):1529–31. CrossRef
28.
Zurück zum Zitat Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal antibodies for multiple sclerosis: an update. BioDrugs. 2019;33(1):61–78. CrossRef Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal antibodies for multiple sclerosis: an update. BioDrugs. 2019;33(1):61–78. CrossRef
31.
Zurück zum Zitat Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–9. CrossRef Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–9. CrossRef
32.
34.
Zurück zum Zitat Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–e85. CrossRef Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–e85. CrossRef
35.
Zurück zum Zitat Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137–52. CrossRef Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137–52. CrossRef
36.
Zurück zum Zitat Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236–43. CrossRef Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236–43. CrossRef
37.
Zurück zum Zitat Cree BA. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis—Commentary. Mult Scler. 2018;24(9):1161–2. CrossRef Cree BA. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis—Commentary. Mult Scler. 2018;24(9):1161–2. CrossRef
Metadaten
Titel
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis
Immunotherapy with rituximab, ocrelizumab, and ofatumumab
verfasst von
Arkady Ovchinnikov
Dr.med. Oliver Findling
Publikationsdatum
20.06.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00939-w